Indoleamine 2,3 Dioxygenase 1 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) – Pipeline Review, H1 2020’, provides in depth analysis on Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Infectious Disease and Metabolic Disorders under development targeting Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

– The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects

– The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BeiGene Ltd

BirchBioMed Inc

Bristol-Myers Squibb Co

CanBas Co Ltd

Eli Lilly and Co

Emcure Pharmaceuticals Ltd

F. Hoffmann-La Roche Ltd

Guangzhou BeBetter Medicine Technology Co Ltd

Hutchison MediPharma Ltd

Incyte Corp

IO Biotech ApS

Jiangsu Hengrui Medicine Co Ltd

Kyowa Kirin Co Ltd

Luye Pharma Group Ltd

Merck & Co Inc

Nammi Therapeutics Inc

Netherlands Translational Research Center BV

NewLink Genetics Corp

Orpheris Inc

Phenex Pharmaceuticals AG

Regen BioPharma Inc

Secarna Pharmaceuticals GmbH & Co. KG

Shanghai De Novo Pharmatech Co Ltd

SignalRx Pharmaceuticals Inc

Suzhou Kintor Pharmaceutical Inc

Syntekabio Inc

Tara Immuno-Oncology Therapeutics LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Overview

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Companies Involved in Therapeutics Development

BeiGene Ltd

BirchBioMed Inc

Bristol-Myers Squibb Co

CanBas Co Ltd

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Incyte Corp

Innovent Biologics Inc

IO Biotech ApS

iTeos Therapeutics SA

Jiangsu Hengrui Medicine Co Ltd

Kyowa Hakko Kirin Co Ltd

Luye Pharma Group Ltd

Merck & Co Inc

Netherlands Translational Research Center BV

NewLink Genetics Corp

Phenex Pharmaceuticals AG

Regen BioPharma Inc

Systimmune Inc

Tempest Therapeutics Inc

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Drug Profiles

(IO-102 + IO-103) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AI-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-0015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BEBT-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-5777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLH-1131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dCellVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-1406131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EOS-200271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epacadostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTI-1090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

indoximod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IO-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IO-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KHK-2455 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linrodostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-01013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3381916 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-7162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLG-802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXD-26116 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-70099 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit IDO1 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO-1 for Lewis Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO1 and DNA for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPST-8844 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Dormant Products

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Discontinued Products

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Product Development Milestones

Featured News & Press Releases

Oct 01, 2018: IO Biotech doses first patient in Phase I/II IO102 and Keytruda trial

Jul 31, 2018: Approval for clinical trial for class I new chemical drug–Anti-Tumor innovative drug (LY01013) in China

Jul 02, 2018: NewLink reports new Phase l positive data from trial for DIPG

Jun 20, 2018: NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting

Jun 06, 2018: De Novo Pharmatech receives approval to initiate clinical trials in China with IDO1/TDO2 inhibitor DN1406131

Jun 04, 2018: NewLink Genetics Announces Final Results from Two Phase 2 Studies of Indoximod Presented at ASCO 2018

May 16, 2018: NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018

Apr 25, 2018: NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting

Apr 25, 2018: Incyte to Present Data on Epacadostat at the 2018 ASCO Annual Meeting

Apr 15, 2018: NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Presented During AACR Plenary

Apr 06, 2018: NewLink Genetics Announces Review of Clinical Programs

Apr 06, 2018: Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

Mar 14, 2018: NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting

Feb 09, 2018: iTeos Therapeutics Provides Update on its IDO1 Inhibitor EOS200271 at Molecular Medicine Tri-Conference

Jan 08, 2018: NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1)

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by BeiGene Ltd, H1 2020

Pipeline by BirchBioMed Inc, H1 2020

Pipeline by Bristol-Myers Squibb Co, H1 2020

Pipeline by CanBas Co Ltd, H1 2020

Pipeline by Eli Lilly and Co, H1 2020

Pipeline by Emcure Pharmaceuticals Ltd, H1 2020

Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, H1 2020

Pipeline by Hutchison MediPharma Ltd, H1 2020

Pipeline by Incyte Corp, H1 2020

Pipeline by IO Biotech ApS, H1 2020

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Pipeline by Kyowa Kirin Co Ltd, H1 2020

Pipeline by Luye Pharma Group Ltd, H1 2020

Pipeline by Merck & Co Inc, H1 2020

Pipeline by Nammi Therapeutics Inc, H1 2020

Pipeline by Netherlands Translational Research Center BV, H1 2020

Pipeline by NewLink Genetics Corp, H1 2020

Pipeline by Orpheris Inc, H1 2020

Pipeline by Phenex Pharmaceuticals AG, H1 2020

Pipeline by Regen BioPharma Inc, H1 2020

Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H1 2020

Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020

Pipeline by SignalRx Pharmaceuticals Inc, H1 2020

Pipeline by Suzhou Kintor Pharmaceutical Inc, H1 2020

Pipeline by Syntekabio Inc, H1 2020

Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020

Discontinued Products, H1 2020

Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports